Stable AAV Vector Production via Engineered Cell Lines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of viral vectors for cell and gene therapy is hindered by the high costs and inefficiencies of transient transfection methods, which require large quantities of DNA and transfection reagents and result in variable viral production due to poor transfection efficiency and cytotoxicity issues with genes like Rep, E2A, and E4 in HEK293 cells.
Innovation Solution
Development of engineered cells with stably integrated polynucleic acids encoding for AAV vector production genes, such as Rep52, Rep78, E2A, and VARNA, linked to chemically inducible promoters, allowing for controlled expression and reducing the need for transient transfection reagents, and the use of HSV-helper systems for enhanced AAV vector production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If transient transfection is used for AAV vector production, then viral vectors can be produced, but production costs increase due to large quantities of DNA and transfection reagents required
Solution Approach 1:
The patent segments the AAV production system into multiple separate plasmids, each expressing a specific viral gene (Rep, E2A, E4, Cap, etc.). This segmentation allows each plasmid to be introduced at lower concentrations through sequential transfection, reducing the total amount of DNA and transfection reagents needed compared to introducing all genes in a single high-concentration transfection event.
Solution Approach 2:
The patent employs preliminary action by first establishing stable cell lines that permanently express the Rep and E2A genes through genomic integration. This preliminary establishment of essential viral functions eliminates the need to repeatedly transfect these genes for each production cycle, significantly reducing the quantity of DNA and transfection reagents required for subsequent AAV production batches.
2Productivity
If transient transfection is used for AAV vector production, then viral vectors can be produced, but transfection efficiency is poor resulting in minimal numbers of transfected cells
Solution Approach 1:
The patent divides the transfection process into multiple sequential steps, introducing plasmids one at a time rather than all simultaneously. This segmentation allows each transfection event to be optimized for higher efficiency, ensuring that cells successfully receive and express each essential gene before the next plasmid is introduced, thereby increasing the number of fully transfected cells.
Solution Approach 2:
The patent uses preliminary action by first establishing stable cell lines with integrated Rep and E2A genes, ensuring that these essential viral functions are reliably present in all cells before proceeding with transient transfection of other genes. This preliminary establishment eliminates variability associated with transient expression of essential genes, improving overall transfection reliability.
3Productivity
If genes like Rep, E2A, and E4 are expressed in HEK293 cells, then AAV vector production is enabled, but cytotoxicity issues arise
Solution Approach 1:
The patent extracts the problematic cytotoxic genes (Rep, E2A, E4) from the transient transfection mixture and places them into stable genomic integration in the HEK293 cell line. By permanently establishing these genes in the cell genome, their expression becomes constitutive and controlled, eliminating the need for high-concentration transient transfection that causes cytotoxicity, while maintaining their essential function for AAV production.
4Productivity
If large quantities of DNA are used for transfection, then viral vector production can proceed, but production costs increase
Solution Approach 1:
The patent uses preliminary action by establishing stable cell lines that permanently harbor the DNA sequences for Rep, E2A, and other essential genes. Once established, these cells continuously produce the necessary viral proteins without requiring additional DNA transfection, dramatically reducing the quantity of DNA needed for each production batch while maintaining high productivity.
Data Source
AI summary
Described herein are AAV vector production systems and HSV-helper systems. Also described herein are engineered cells and kits comprising an AAV vector production system and/or an HSV-helper system and methods of using the same for AAV vector production.